Better treatments are needed for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of failing standard therapy. Avoiding apoptosis is a hallmark of cancer, and in DLBCL the redundantly functioning antiapoptotic proteins BCL2 and MCL1 are frequently expressed. Here we explore drugs that cause loss of MCL1, particularly the potent new cyclin-dependent kinase inhibitor dinaciclib, which knocks down MCL1 by inhibiting CDK9. Dinaciclib induces apoptosis in DLBCL cells but is completely overcome by increased activity of BCL2. We find that clinical samples have frequent co-expression of MCL1 and BCL2, suggesting that therapeutic strategies targeting only one will lead to treatment failures owing to activity of the other. The BH3 mimetic ABT-199 potently and specifically targets BCL2. Single-agent ABT-199 had modest antitumor activity against most DLBCL lines and resulted in compensatory upregulation of MCL1 expression. ABT-199 synergized strongly, however, when combined with dinaciclib and with other drugs affecting MCL1, including standard DLBCL chemotherapy drugs. We show potent antitumor activities of these combinations in xenografts and in a genetically accurate murine model of MYC-BCL2 double-hit lymphoma. In sum, we reveal a rational treatment paradigm to strip DLBCL of its protection from apoptosis and improve outcomes for high-risk patients.
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, making up~30 percent of lymphoma diagnoses in western countries. Up-front chemoimmunotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) generates long-term disease-free survival in~60% of patients. [1] [2] [3] Relapsed or refractory patients, however, have poor prognosis, with only~10% ultimately achieving cure, requiring aggressive salvage chemotherapy and transplant consolidation. 4 Patients at high risk of failing R-CHOP can be identified before treatment with the International Prognostic Index risk score, gene expression profiling to determine cell of origin (COO) and immunohistochemical staining patterns, among other methods. 5 Clinical efforts to improve outcome for these patients have largely involved intensification, modification, or replacement of the CHOP backbone. 6 Although such alternatives may be offered by particular practitioners, none is recognized as a separate standard of care for high-risk disease, and prognosis for high-risk patients remains markedly compromised in the post-rituximab era. 7 Although DLBCL has two major COO subtypes with disparate pathogenesis, recent clinicopathologic studies suggest that mechanisms underlying high-risk disease are more unified. For example, co-expression of c-MYC and BCL2 detected by immunohistochemistry (IHC) is a negative prognostic finding independent of COO. 8, 9 A study of 893 cases highlighted increased frequency of MYC-BCL2 co-expression in the activated B-cell (ABC) subtype being one possible reason for its worse prognosis compared with the germinal center B-cell (GCB) subtype. 10 In addition, an elegant analysis by Monti et al. found cases carrying complex patterns of cytogenetic alterations had markedly worse prognosis, and this again was independent of COO. 11 Apoptotic defects are required for tumorigenesis, 12 and in DLBCL the best annotated antiapoptotic mechanism in clinical samples is overexpression of BCL2 or its functionally redundant family member MCL1. BCL2 and MCL1 are a part of the BCL2 protein family, which regulates activation of the intrinsic apoptosis pathway, in which release of cytochrome c from the mitochondria triggers a protease cascade ending in cell death. 13 BCL2 and MCL1 both suppress apoptosis by sequestering the BH3-only protein BIM, which activates mitochondrial outer membrane permeabilization by the multi-domain pro-apoptotic proteins BAK and BAX. BCL2 is expressed in 40-80% of DLBCL, owing to t(14;18)(q32;q21) found in 15-30% of cases, and through additional mechanisms that are not well defined. [8] [9] [10] 14 Frequent MCL1 expression in DLBCL, meanwhile, has been recognized for some time but was only recently quantified in a larger case series, showing IHC positivity in 50% of ABC and 30% of GCB tumors. 15 In this study, we tested the potent and specific multi-CDK inhibitor dinaciclib 16 and found broad ability to trigger apoptosis in DLBCL cell lines associated with lost MCL1 protein owing to CDK9 inhibition. Correspondingly, BCL2 overexpression eliminated the activity of dinaciclib, and examination of BCL2 and MCL1 protein expression revealed that DLBCL clinical samples can express either or both at high levels. We hypothesized combined targeting of MCL1 expression with dinaciclib and BCL2 activity with the third-generation BH3 mimetic ABT-199 that would show greater antitumor activity than either alone. We found potent synergy in vitro and in vivo of this combination against both xenografted high-risk DLBCL cell lines and in an immunocompetent mouse model of MYC-BCL2 double-hit lymphoma. We extended our findings to combinations of ABT-199 with chemotherapy drugs that affect MCL1, revealing multiple potential therapeutic combinations that could be evaluated in patients.
MATERIALS AND METHODS

Cell lines
Cell culture conditions are described in Supplementary Data on the Leukemia website. All human DLBCL lines were subjected to short tandem repeat fingerprinting as described, 17 with results compared with public databases. Short tandem repeat results are provided as Supplementary Table S1 .
Drugs
Dinaciclib, doxorubicin, etoposide, cytarabine, flavopiridol, SNS-032 and PHA-767491 were purchased from Selleck Chemicals (Houston, TX, USA). ABT-199 was kindly provided by AbbVie Inc. (North Chicago, IL, USA).
Overexpression of BCL2 and MCL1 and selection BCL2 and MCL1 complementary DNAs were purchased from DNASU Plasmid Repository (Tempe, AZ, USA) and cloned to pMIG vector. SU-DHL-4, TMD8, Riva and U2932 cells were engineered to express the murine ecotropic receptor as previously described to permit efficient retroviral introduction (reagents a kind gift of the Staudt laboratory). 18 Cells were treated with dinaciclib, ABT-199 or combination for 24 h and allowed to recover. Green fluorescent protein (GFP) expression was assessed before drug treatment (initial infection) and after drug recovery through fluorescence-activated cell sorting analysis (Guava EasyCyte; Millipore, Billerica, MA, USA). Data are reported as fold change in GFP in the main figures, with raw GFP results provided in the supplementary data.
Immunohistochemistry
Tumors from mice were prepared for hematoxylin and eosin, Ki67, MCL1 and cleaved caspase-3 staining by the University of Arizona Cancer Center Tissue Acquisition Cellular/Molecular Analysis Shared Resource using standard techniques. MCL1 IHC was performed as described. 15 Staining intensity was scored by expert lymphoma hematopathologist (LMR) as 0-3 per core, and the score for each case represents an average of 2 cores. We defined score categories as negative (o1), intermediate (1) and high (41) .
Viability and apoptosis
Cells plated at 5000 per well were exposed to serial drug dilutions and assessed for viability using CellTiter-Glo reagent (Promega, Madison, WI, USA) by the manufacturer's protocol. Apoptosis was assessed by flow cytometry on Guava EasyCyte using the Guava Nexin Reagent (Millipore) by the manufacturer's protocol.
Quantitative real-time PCR RNA was extracted using RNeasy Mini Kit according to the manufacturer's specifications (Qiagen, Hilden, Germany). Complementary DNAs were synthesized using TaqMan Reverse Transcription Reagents as directed by the protocol provided by the manufacturer (Life Technologies, Carlsbad, CA, USA). Quantitative PCR was carried out using TaqMan Gene Expression Assays (Life Technologies) and the Applied Biosystems (Life Technologies) 7500 Real-Time PCR System. Cycle threshold (Ct) values were calculated for each gene, and normalized to the reference gene GAPDH, and relative gene expression was determined using the ddCt method.
In vivo studies
All animal experiments were conducted in accordance with guidelines of the University of Arizona Institutional Animal Care and Use Committee. Female severe combined immunodeficient mice were flank injected with 2 × 10 6 cells. Tumors were generated using VavP-Bcl2 transgenic hematopoietic stem cells as previously described. [19] [20] [21] Tumor-bearing mice for drug treatment were generated via tail vein injection of tumor cells from primary mice to secondary recipients following 3G preparative irradiation. Drug administration protocols are described in Supplementary Data 
RESULTS
Dinaciclib treatment of DLBCL causes rapid loss of MCL1 and apoptosis in vitro and in vivo We tested 23 DLBCL cell lines for sensitivity to dinaciclib and compared its activity with that of flavopiridol. 22 Because of dinaciclib's short half-life in vivo, 16 we assessed viability at 24 h. Overall, sensitivity to both drugs was independent of COO, and dinaciclib was significantly more potent ( Figure 1a ). Sensitivity patterns between the two drugs, however, are highly correlated (P = 0.0001, Figure 1a , inset). Multiple prior studies have shown flavopiridol and other CDK inhibitors including dinaciclib promote apoptosis of tumor cells owing to decline of MCL1 protein resulting from inhibition of CDK9, which phosphorylates RNA polymerase II to promote transcriptional elongation. [23] [24] [25] [26] Dinaciclib's in vivo antitumor activity in particular is known to be MCL1 dependent because of pharmacokinetic properties producing limited clinical duration of exposure. 27 We investigated the timeand dose-dependent effects of dinaciclib and found exposure of either SU-DHL-4 (sensitive GCB cells) or TMD8 (sensitive ABC cells) to dinaciclib for 6 h results in loss of phospho-RNA polymerase II and MCL1 protein, whereas more stable BCL2 was unaffected even at 200 nM for 24 h (Figure 1b To further assess dinaciclib's therapeutic potential, we xenografted SU-DHL-4 cells to severe combined immunodeficient mice, pair-matched animals by tumor size after engraftment and treated them with dinaciclib vs vehicle (n = 9 per group). We dosed dinaciclib every other day (20+20 mg/kg split dosing) 28 on the indicated days, resulting in markedly reduced tumor burden compared with vehicle ( Figure 1f ). There were no major differences in mean weight (Supplementary Figure S1d) . We killed two animals from each group on day 16, 4 hours after drug or vehicle dosing, for pathologic assessment. Dinaciclib-treated tumors appear more disorganized and necrotic on standard BCL2 activity mediates resistance to dinaciclib in DLBCL To understand the basis of dinaciclib resistance, we assessed its effects on resistant lines. Like sensitive lines, Riva and U2932 cells experience loss of phospho-RNA polymerase II and MCL1 but greatly reduced or absent PARP cleavage ( Figure 2a) . As in the sensitive lines, BCL2 levels were not affected. Lymphoma cells dependent on multi-domain antiapoptotic proteins, usually BCL2 or MCL1, have been described as 'poised for death', because the intrinsic apoptotic pathway is intact and ready to trigger without the protection they provide. 29 Our data show MCL1 loss owing to dinaciclib is sufficient to trigger apoptosis in some DLBCL cell lines but not others. We hypothesized BCL2's ability to compensate functionally for MCL1 is a major factor in determining sensitivity. We determined relative expression of MCL1 and BCL2 by quantitative PCR in the 23 DLBCL cell lines and tested for association with dinaciclib sensitivity. Increased BCL2 but not MCL1 expression associated strongly with increased dinaciclib IC 50 (P = 0.0068, Figure 2b ). Association between messenger RNA and protein levels was strong for BCL2 but less so for MCL1, whose protein levels are translationally regulated (Supplementary Figure  S2a) . 30, 31 We retrovirally introduced BCL2-GFP to sensitive and resistant cells and treated them with dinaciclib for 24 h. After recovery, sensitive cells showed strong enrichment of GFP-positive populations in contrast to resistant Riva or U2932 cells (Figure 2c , Supplementary Figures S2b and c) . Consistently, we isolated 100% BCL2-GFP+ SU-DHL-4 and TMD8 cells and found them insensitive to dinaciclib, showing a viability response similar to Riva and U2932 (Figure 2d ). BCL2 activity alone, therefore, can eliminate the antitumor effects of dinaciclib in sensitive cells. Like parent cells, the BCL2-overexpressing cells lost MCL1 protein in response to dinaciclib but had greatly reduced PARP cleavage (Figure 2e ). Taken together, our data highlight key therapeutic implications of the ability of BCL2 and MCL1 to compensate for each other functionally in protecting cells from apoptosis.
Co-expression of MCL1 and BCL2 is frequent in DLBCL clinical tumor samples Although MCL1 or BCL2 expression in DLBCL clinical samples has been described, the relationship between the two, to our knowledge, has not been analyzed. We performed MCL1 protein staining on tissue microarrays containing DLBCL cases for which BCL2 IHC results have been reported. 32 We scored MCL1 as high, intermediate or negative (Figure 3a) . Consistent with a recent report, 15 we found higher levels of MCL1 were more common in non-GCB cases (Figure 3b ). Of 59 cases stained successfully for both BCL2 and MCL1, 15 were BCL2 IHC positive, defined as ⩾ 50% of tumor cells positive using the standard monoclonal mouse 124 antibody. 32 MCL1 staining was not different between BCL2-positive and BCL2-negative cases, with 10/15 (67%) of BCL2-positive and 25/44 (57%) of BCL2-negative cases being either MCL1 high or intermediate (P = 0.5576, Figure 3c ). Therefore, despite the redundant antiapoptotic functions of MCL1 and BCL2, there is no indication of mutually exclusive expression in DLBCL, with cases able to express either or both together at high levels.
Combined targeting of MCL1 and BCL2 with dinaciclib and ABT-199 is highly effective against DLBCL in vitro and in vivo These data suggest that targeting either MCL1 or BCL2 alone in DLBCL will select for cell populations able to express the other, Drug combinations induce apoptosis in lymphoma L Li et al leading to treatment failure, but combined targeting of both simultaneously may be more effective. ABT-199 is a BH3 mimetic in clinical trials that potently inhibits BCL2 while avoiding offtarget activity against other BCL2 family members, particularly BCL-X L . Thrombocytopenia owing to off-target activity against BCL-X L limited the clinical utility of ABT-199's predecessor ABT-263 (navitoclax). 33 We evaluated ABT-199 against our DLBCL lines and found generally lower potency than dinaciclib (Figure 4a ). Viability curves show rapid decline in sensitive cells as they reach IC 50 but no effect on resistant cells, and sensitive cells are highly apoptotic Drug combinations induce apoptosis in lymphoma L Li et al after 24-h ABT-199 exposure, in contrast to resistant cells (Figure 4b ). SU-DHL-4 contains t(14;18) and previously was reported to be BCL2 dependent based on BH3 profiling, 29 but recently published data, like ours, showed insensitivity to BH3 mimetics. 33 To further evaluate compensation between BCL2 and MCL1, we incubated SU-DHL-4 cells with and without ABT-199 and found drug-induced MCL1 protein upregulation starting within 6 h of exposure as well as BCL2 upregulation to a lesser extent (Figure 4c ).
These data further highlight a need for simultaneous targeting of MCL1 and BCL2 for therapeutic success in DLBCL. We, therefore, combined ABT-199 and dinaciclib against cells sensitive and resistant to both drugs as single agents (Figure 4d) . In dinaciclibsensitive cells (SU-DHL-4 and TMD8) or ABT-199-sensitive cells (Riva), addition of the other drug resulted in little further loss of viability and was non-synergistic or weakly synergistic. In U2932 cells, however, resistant to both drugs as single agents, the combination was highly potent and synergized strongly. The same was true for SU-DHL-4 and TMD8 cells engineered to overexpress BCL2. Introduction of either MCL1 or BCL2 to U2932 cells led to enrichment in response to combined dinaciclib+ABT-199 but not either single agent, further highlighting the central importance of these apoptotic mediators to the antitumor effects of the combination (Figure 4e, Supplementary Figure S3a ; dinaciclib results in 1e and 2c). To further evaluate the basis for synergy, we tested three additional drugs with activity against CDK9. Flavopiridol inhibits CDKs and several other kinases, although its antitumor effects in lymphoid cells are owing to CDK9 and loss of MCL1. 22, 23, 25 PHA-767491 is a dual inhibitor of CDC7 and CDK9, 34 whereas SNS-032 has activity against CDK2, CDK7 and CDK9. 35, 36 All three synergized strongly with ABT-199 against U2932 cells (Figure 4f ). Flavopiridol and SNS-032 also synergized strongly with ABT-199 against BCL2-overexpressing SU-DHL-4 and TMD8 cells, with PHA-767491 results less clear (Supplementary Figure S3b) . Because CDK9 is the only common target among all four drugs, these data strongly argue that its inhibition and resulting loss of MCL1 is the basis for dinaciclib's synergy with ABT-199. We chose U2932 as a model of high-risk disease for initial evaluation in vivo as both dinaciclib and ABT-199 showed poor single-agent activity against these cells in vitro. We xenografted 20 severe combined immunodeficient mice with U2932 cells and matched them by tumor size to four groups: control (IP vehicle/PO vehicle), dinaciclib (IP dinaciclib/PO vehicle), ABT-199 (IP vehicle/ PO ABT-199) and combination (IP dinaciclib/PO ABT-199). Combination therapy produced markedly superior tumor control (Figure 4g , n = 5 per group) and importantly no overt signs of toxicity, with animal weights similar between groups (Supplementary Figure S3c) . Combined targeting of MCL1 expression and BCL2 activity, therefore, is achievable in vivo and generates potent activity against tumors representing highrisk DLBCL.
High efficacy of targeting both MCL1 and BCL2 in a model of MYC-BCL2 double-expressing lymphoma Double-hit lymphoma is a subset of aggressive B-lymphoma overlapping with DLBCL carrying simultaneous presence of two chromosomal translocations involving the immunoglobulin heavy chain locus and c-MYC, BCL2 or BCL6. The combination of t(14;18) (q32;q21) involving BCL2 and t(8;14)(q24;q32) involving c-MYC is most common.
37 Double-hit lymphoma responds poorly to standard chemoimmunotherapy with long-term survival in at best a quarter of patients, representing arguably the highestrisk group of DLBCL and similar cancers. 8, 9, 37 We retrovirally introduced c-MYC into hematopoietic stem cells derived from VavP-BCL2 mice 38 as previously described [19] [20] [21] and transplanted sub-lethally irradiated wild-type recipients (Figure 5a ). MYC expression resulted in rapid lymphoma onset in recipient animals, with 100% penetrance by day 50 post-transplant (Figures 5b and c) . Pathologic assessment showed a diffuse large B-cell tumor, highly proliferative and invasive to other organs, in contrast with noninvasive vector tumors that grow in a follicular pattern similar to baseline VavP-BCL2 animals (Figure 5d ). 38 This model, therefore, recapitulates the genetics, pathology and aggressive behavior of MYC-BCL2 double-hit lymphoma in an immunocompetent animal system.
Oncogenic synergy between MYC and BCL2 was recognized nearly three decades ago owing to BCL2's ability to prevent apoptosis resulting from high MYC activity. 39 We hypothesized the inhibition of BCL2 with ABT-199 would be effective against tumor cells derived from VavP-BCL2/c-MYC-transplanted animals. Strikingly, however, these tumor cells were mostly insensitive to singleagent ABT-199 (Figure 5e ). Activity of single-agent dinaciclib, meanwhile, was consistent with a cytostatic effect. The combination, however, promoted strong synergy. A recent study in MYCdriven lymphoma showed particular dependence of these tumors on MCL1. 40 Our data suggest that even with constitutive BCL2 expression promoting tumor formation, MCL1 maintains an important role in protecting cells from apoptosis. Consistently, we find dinaciclib-sensitive MCL1 expression in tumors derived from VavP-BCL2/c-MYC-transplanted animals, whereas dinaciclibinsensitive BCL2 expression prevents significant PARP cleavage (Figure 5f) . We, therefore, tested dinaciclib+ABT-199 in vivo. Tumor-bearing animals treated with either dinaciclib/oral vehicle (n = 7) or ABT-199/intraperitoneal (IP) vehicle (n = 6) showed no survival difference from those treated with oral vehicle/IP vehicle (n = 7, Figure 5g ). Those treated with ABT-199/dinaciclib (n = 8), however, had greatly improved survival (Po 0.0001) and markedly increased clearing of tumor cells from the peripheral blood (Figure 5h) . Inhibition of BCL2 alone, therefore, was inadequate therapy in an model of MYC-BCL2 double-hit DLBCL owing to expression of MCL1 associated with high MYC activity, but combination with therapy promoting MCL1 loss was significantly more effective. Chemotherapy drugs affecting MCL1 levels synergize strongly with ABT-199 Dinaciclib and ABT-199 are unapproved drugs that cannot easily be combined in a clinical trial. Trials are underway or planned, however, combining ABT-199 with chemotherapy in B-NHL (NCT01594229, NCT01671904, NCT02187861 and NCT02055820). We, therefore, investigated whether our findings can help predict activity and inform trial design for such combinations. The anthracycline doxorubicin is considered the most active drug in R-CHOP and is known to have global effects on transcription that can result in reduced MCL1. 41 Comparison of doxorubicin's activity with dinaciclib's in DLBCL cell lines shows correlation (P = 0.0238), suggesting overlapping mechanism (Figure 6a ). Similar to dinaciclib, doxorubicin caused loss of MCL1 at peak concentrations, and had no effect on BCL2 (Figure 6b ). R-CHOP+navitoclax in vivo vs xenografted mantle cell lymphoma cells previously was shown to be more potent than either alone. 42 We found doxorubicin behaved like dinaciclib when combined with ABT-199, adding little to the ABT-199-sensitive Riva cells but synergizing against resistant U2932 and MYC-BCL2 murine tumor cells (Figure 6c ). Etoposide and cytarabine are the key components of DLBCL salvage regimens RICE 43 and R-DHAP, respectively, and also can have global effects on transcription resulting in loss of MCL1. 45 These drugs behaved nearly identically to doxorubicin and dinaciclib in combination studies with ABT-199 (Figures 6d and e) . Notably, dinaciclib combined poorly with the same chemotherapy drugs, failing to promote a significant loss in viability in either Riva or U2932 cells (Supplementary Figure S4) . In sum, these data provide a basis to expect heightened therapeutic activity when ABT-199 is combined with chemotherapy drugs that affect MCL1. Until a more specific approach like dinaciclib to inhibit MCL1 transcription is available for combination with ABT-199, these findings can inform ABT-199+chemotherapy strategies for high-risk DLBCL.
DISCUSSION
Improving outcome for high-risk DLBCL requires addressing underlying causes of poor response to standard therapy. Resistance to apoptosis is a hallmark of cancer 12 and can promote escape from otherwise toxic therapies. Overexpression of multidomain antiapoptotic proteins like BCL2 and MCL1 is a primary route to those ends. Despite their redundant function in apoptosis, however, we find both proteins can be expressed simultaneously in DLBCL tumors. A caveat to IHC is that it provides a snapshot in time of protein expression in particular tumors and not necessarily fixed properties. Instead, both our data and the work of others show that DLBCL cells have high propensity to express either or both these proteins to avoid programmed cell death, especially the poor-prognosis ABC subtype. 10, 15 Therefore, therapeutic targeting of either BCL2 or MCL1 alone seems destined to select for treatment failure driven by tumor populations able to express the other. Our study of the combined approach builds on work of others, who showed synergy using on older drugs (flavopiridol, roscovitine and navitoclax) whose offtarget toxicities have prevented advancement to clinical approval. 42, 45, 46 We now refine and improve the strategy using the newer more potent and specific inhibitors dinaciclib and ABT-199. By undertaking extensive in vivo analysis in independent, complementary model systems, we also provide a stronger basis for moving forward with clinical evaluation specifically in DLBCL.
Dinaciclib inhibits CDK1, 2, 5 and 9 with greater potency and specificity than flavopiridol or roscovitine and has a far superior therapeutic index in vivo. 16 It has progressed through phase I clinically, where limited bone marrow suppression and electrolyte abnormalities were the main toxicities, 26, 47 and is now in phase 2 in combination with other therapies for multiple myeloma and solid tumors (NCT01783171, NCT01711528 and NCT01434316). Although dinaciclib's four targets could produce diffuse effects on tumor cell proliferation and survival, its effects on CDK9 leading to rapid loss of MCL1 predominate particularly in vivo where pharmacokinetics limit clinical duration of exposure. 27 ABT-199, meanwhile, is a BH3 mimetic whose ability to spare platelets by avoiding anti-BCL-X L activity has enabled dramatic phase I activity against chronic lymphocytic leukemia (CLL). As such, the main dose-limiting toxicity of ABT-199 in CLL is tumor lysis syndrome (TLS), which can be seen in particularly susceptible CLL patients after a single oral dose. TLS also has been reported for dinaciclib 26 and flavopiridol 48 in CLL, interestingly, so it is possible this toxicity is more disease specific than drug specific. Either way, the clinical experience with ABT-199 shows CLL's particular dependence on BCL2, whereas apoptosis protection in DLBCL and most other cancers is more complex. Results for ABT-199 in DLBCL have been reported for only nine relapsed or refractory patients, of whom three responded (3/8 treated with ⩾ 600 mg daily, including one complete response), and TLS was not a significant issue. 49 We found modest single-agent activity of ABT-199 against most DLBCL cell lines at 24-h incubation, and our BCL2-MYC mouse model was more resistant in vivo than was reported recently for a genetically similar model. 50 What's more important, however, is that ABT-199 in combination with MCL1 knockdown by dinaciclib resulted in strong synergy in all cases. Importantly, our in vivo experiments show that significant antitumor activity of the combination is achievable without undue toxicity to host animals. ABT-199 plus dinaciclib cannot easily be tested in patients in the near term until at least one of the drugs is approved, but more important is the principle of high antitumor activity when ABT-199 is combined with any drug resulting in a decrease of MCL1. By expanding our studies to ABT-199 plus chemotherapy agents with this activity, we show a short-term path to assess this strategy clinically until such time as assessment of the specific ABT-199-dinaciclib combination can be undertaken.
